Stephen Lee, MD
Gynecologic Oncology · Duarte, CANPI 1114185923
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,200 of the $22,138 with a category attached, or 73.2%. Johnson & Johnson accounts for 68.5% of it on its own, with 9 other manufacturers making up the rest.
Across 53 payments — averaging $417.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$15K
- Intuitive Surgical$5K
- Ethicon Endo-surgery Inc.$1K
- Davol Inc.$270
- GSK$101
- Merck$57
- plus $100 from 4 others
Across 1 payment — averaging $600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$600
What the payments were for
- Consulting fees$16,20073%
- Travel & lodging$4,27919%
- Food & beverage$6583%
- Education$1,0005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 24 | $15,168 |
| Intuitive Surgical | 17 | $5,392 |
| Ethicon Endo-surgery Inc. | 1 | $1,050 |
| Davol Inc. | 2 | $270 |
| GSK | 1 | $101 |
| Merck | 3 | $57 |
| Tesaro, Inc. | 2 | $41 |
| AbbVie | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Avion Pharmaceuticals | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,174
- DAVINCI XI$1,000
- ARISTA AH FLEXITIP$270
- ZEJULA$101
- JEMPERLI$101
How this compares
$22,138 in reported general payments places this provider in the 80th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Duarte
- Mihae SongDuarte$3K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.